Clinical Trials Evaluating the Effect of Metformin Treatment on Function Endometrium in Women Diagnosed With Idiopathic Infertility (METIN)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT06012682 |
Recruitment Status :
Not yet recruiting
First Posted : August 25, 2023
Last Update Posted : August 25, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Infertility, Female | Drug: Metformin Hydrochloride Drug: Placebo | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 200 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Randomized, Controlled, Double-blind Study Clinical Trials Evaluating the Effect of Metformin Treatment on Function Endometrium in Women Diagnosed With Idiopathic Infertility |
Estimated Study Start Date : | August 30, 2023 |
Estimated Primary Completion Date : | September 30, 2027 |
Estimated Study Completion Date : | September 30, 2027 |
Arm | Intervention/treatment |
---|---|
Experimental: metformin
patients randomized to received metformin
|
Drug: Metformin Hydrochloride
The investigational medicinal product/placebo will be dispensed to study participants by study staff during randomization visits V1, V2, V3, V4, V5 and V6. The randomized patient will receive the investigational medicinal product/placebo in tablets of 500 mg. The received tablets will be dispensed in an amount sufficient for the next visit. Patients will be asked to bring unused medicine and all empty ones packaging to the Center for each subsequent visit. The investigational medicinal product/placebo will be administered orally 500 mg three times a day (Table No. 1). The dose of the study product will be gradually increased from 500 mg/day to 1500 mg/day in order to avoid or reduce side effects related to taking the study medicinal product metformin |
Placebo Comparator: placebo
patients randomized to received placebo
|
Drug: Placebo
The investigational medicinal product/placebo will be dispensed to study participants by study staff during randomization visits V1, V2, V3, V4, V5 and V6. The randomized patient will receive the investigational medicinal product/placebo in tablets of 500 mg. The received tablets will be dispensed in an amount sufficient for the next visit. Patients will be asked to bring unused medicine and all empty ones packaging to the Center for each subsequent visit. The investigational medicinal product/placebo will be administered orally 500 mg three times a day (Table No. 1). The dose of the study product will be gradually increased from 500 mg/day to 1500 mg/day in order to avoid or reduce side effects related to taking the study medicinal product metformin |
No Intervention: group without intervention |
- Effects of metformin on fertility and the possibility of becoming pregnant,as measured by pregnancy test strips and β-hCG levels [ Time Frame: 4 years ]The aim of the study is to evaluate the effect of metformin on endometrial function in women diagnosed with idiopathic infertility, by proving the use of the proposed therapy to improve fertility in these women.
- Evaluation of the effect of metformin therapy on endometrial function. [ Time Frame: 4 years ]It will be tested by assessing the concentration of biomarkers in the tissue before and after treatment
- Molecular analysis of endometrial tissues using Next Generation Sequencing (NGS) technology [ Time Frame: 4 years ]Transcriptome analysis of endometrial tissues before and after metformin therapy.
- Intra-tissue metabolic profiling of steroids [ Time Frame: 4 years ]The study will test whether treatment with metformin affects the intracrine production of steroid hormones in the endometrium.
- Oxidative stress evaluation by using total oxidative capacity (TOC) and total antioxidant capacity (TAC) [ Time Frame: 4 years ]In-depth analysis of molecular and cellular processes using multi-omics combined with clinical data will provide essential knowledge about the mechanisms of metformin's action, which may have clinical applications not only in cases of idiopathic female infertility but also in other disorders.
- Quality of Life questionary evaluation SF-36, FertiQoL, [ Time Frame: 24 weeks ]The results on the response scales are rotatable, summed and scaled from 0 to 100. Subscale and higher scores indicate good quality life. The number of obtained equation points is 50 or less arrangements with a psychologist.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 45 Years (Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Age 18-45
- No pregnancy for a minimum of 12 months prior to screening.
- Diagnosed with idiopathic infertility.
- No use of hormone therapy 30 days before screening.
- No use of any methods of contraception 30 days before screening and during the examination.
- BMI between 18.5 - 30 kg/m2.
Exclusion Criteria:
- Positive pregnancy test result.
- Patients diagnosed with another factor of infertility.
- Patients with type I or II diabetes.
- Patients taking metformin or other hypoglycaemic drugs in the last 4 weeks before screening.
- Patients with hepatic impairment and abnormal liver function tests (alanine aminotransferase and/or aspartate aminotransferase (above 3x ULN).
- Patients with an eGFR less than 45 mL/min/1.73m2.
- Accompanying chronic diseases with poor prognosis.
- Patients with a history of lactic acidosis or other metabolic acidosis.
- Patients with a history of congestive heart failure III/IV NYHA degree.
- Patients with acute myocardial ischemia.
- Patients with sepsis or severe infection.
- Diseases which, in the opinion of the investigator, constitute an exclusion criterion and prevent the patient from participating in the study.
- Patients with predictable problems with cooperation with the research team.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06012682
Contact: Monika Zbucka-Krętowska, Associate Professor | +48 85 831 87 89 | monika.zbucka-kretowska@umb.edu.pl | |
Contact: Clinical Research Support Center | +48 85 686 53 86 | owbk@umb.edu.pl |
Responsible Party: | Medical University of Bialystok |
ClinicalTrials.gov Identifier: | NCT06012682 |
Other Study ID Numbers: |
2021/ABM/03/00006 |
First Posted: | August 25, 2023 Key Record Dates |
Last Update Posted: | August 25, 2023 |
Last Verified: | August 2023 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Infertility Infertility, Female Genital Diseases Urogenital Diseases Genital Diseases, Female |
Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Metformin Hypoglycemic Agents Physiological Effects of Drugs |